SCHEMBL755519

SCHEMBL755519

CC[C@@H](C)Oc1cccc(CCl)c1

nearest known ligand 0.51

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
GPBAR1 Q8TDU6 1/20 0.44
CYSLTR1 Q9Y271 1/20 0.44
TAAR1 Q96RJ0 2/20 0.41
GRM2 Q14416 1/20 0.40
GAA P10253 1/20 0.39
HSD17B10 Q99714 1/20 0.39
MTNR1A P48039 6/20 0.38
MTNR1B P49286 6/20 0.38
ALDH1A1 P00352 2/20 0.38
HTT P42858 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
P2RX3 P56373 1/20 0.37
TTR P02766 1/20 0.37
MAPT P10636 1/20 0.36
ADORA3 P0DMS8 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4563251 1.00 GPBAR1 (0.44) GPBAR1CYSLTR1TAAR1GRM2GAA
SCHEMBL12327116 0.86 MAPK1 (0.47) GPBAR1CYSLTR1TAAR1GRM2GAA
SCHEMBL757234 0.84 P2RX3 (0.49) TAAR1GAAHSD17B10ALDH1A1HTT
SCHEMBL3479629 0.83 TAAR1 (0.42) TAAR1MTNR1AMTNR1BALDH1A1HTT
SCHEMBL4562863 0.83 TAAR1 (0.42) TAAR1MTNR1AMTNR1BALDH1A1HTT
SCHEMBL11665507 0.83 GPBAR1 (0.55) GPBAR1CYSLTR1GRM2GAAHSD17B10
SCHEMBL758042 0.83 TSHR (0.44) GPBAR1CYSLTR1TAAR1GRM2GAA
SCHEMBL13803187 0.83 TSHR (0.44) GPBAR1CYSLTR1TAAR1GRM2GAA
SCHEMBL28121075 0.83 TAAR1 (0.45) GPBAR1CYSLTR1TAAR1GRM2GAA
SCHEMBL27987188 0.83 TAAR1 (0.45) GPBAR1CYSLTR1TAAR1GRM2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8211904-B2 Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease Merck, Sharp & Dohme Corp. (US) 2012-07-03 US disclosed
US-8211904-B2 Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease Merck, Sharp & Dohme Corp. (US) 2012-07-03 US disclosed
EP-1910364-B1 SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME (US) 2012-03-21 EP disclosed
US-20100298342-A1 Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease MERCK & CO., INC. (US) 2010-11-25 US disclosed
US-20070021454-A1 Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease MERCK SHARP & DOHME LLC 2007-01-25 US disclosed
WO-2007011833-A2 SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE MERCK & CO., INC. (US) 2007-01-25 WO disclosed
US-20070021454-A1 Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease MERCK SHARP & DOHME LLC 2007-01-25 US disclosed
US-20070021454-A1 Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease MERCK SHARP & DOHME LLC 2007-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021454-A1 Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease BACE1, APP, PSEN1 GPBAR1 656/4885CYSLTR1 4018/4885TAAR1 1038/4885
US-20100298342-A1 Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease BACE1, APP, PSEN1 GPBAR1 656/4885CYSLTR1 4018/4885TAAR1 1038/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.